en · de · es · fr · pt
cjc-1295-notes.peptides4800.com › News › Albumin Binding And Duration Of Action — Hands-On Walkthrough

Albumin Binding And Duration Of Action — Hands-On Walkthrough

By Editorial Desk · published 2026-04-17 · last reviewed 2026-06-01 · News

If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-06-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Albumin Binding and Duration of Action

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Analytical Characterization and Storage

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Cjc-1295 at a glance

PropertyValueNotes
Duration with linkerSeveral daysReported in early human work
Duration without linkerTens of minutesShort plasma residence
Albumin attachment siteCysteine-34Covalent maleimide reaction
Primary receptorPituitary GHRH receptorStimulates growth hormone release
Downstream markerInsulin-like growth factor 1Indirect measure of activity

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Related pages on this site

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Background from the literature

== Development == C-4 is a member of the Composition C family of chemical explosives. Variants have different proportions and plasticisers and include compositions C-2, C-3, and C-4. The original RDX-based material was developed by the British during World War II and redeveloped as Composition C when introduced to the U.S. military. It was replaced by Composition C-2 around 1943 and later redeveloped around 1944 as Composition C-3. The toxicity of C-3 was reduced, the concentration of RDX was increased, giving it improved safety during usage and storage. Research on a replacement for C-3 was begun prior to 1950, but the new material, C-4, did not begin pilot production until 1956. C-4 was submitted for patent as "Solid Propellant and a Process for its Preparation" March 31, 1958, by the Phillips Petroleum Company.

== Risk factors affecting food distribution and examples of failed policy == Prominent risk factors that can affect the food distribution within a society include war, economic failure, political instability, and weather conditions. Each of these factors affects individual groups of people differently, but all share the common attribute of being detrimental to local food distribution and food systems. Two prominent examples of risk factors' negative effect on a society's food distribution system are the situation in Japan during World War II and Africa during the late 1970s and early 1980s.

Before leaving for the Philippines, the men received further instructions and physical examinations in Camp Stoneman in Pittsburg, California, in March 1945. The men left for the Philippines on the troop ship S.S. Fairisle on March 27, 1945. The squadron arrived in Manila on April 30, 1945, and was assigned to the Fifth Air Force's 58th Fighter Group, based at Porac, Pampanga, in the Clark Field complex on the island of Luzon. Thus, the 201st Squadron of the Mexican Expeditionary Air Force, composed of about 300 men, 30 pilots and 25 U.S.-made P-47D Thunderbolt aircraft, fought against Imperial Japanese Army forces during the Battle of Luzon in pursuit of the liberation of the Philippines. The P-47D aircraft carried USAAF insignia but with Mexican colors on the tail rudder.

== Capabilities == OpenELIS covers the laboratory testing workflow, including patient and sample management, results entry and validation, quality control, and reporting, and consolidates clinical, environmental, and vector-surveillance testing on a single platform, an approach the project describes as "One Health". Quality-control features include reference-range enforcement, Westgard-rule monitoring with Levey–Jennings charts, and corrective-action tracking used to support ISO 15189 and SLIPTA accreditation.

=== Rearrangement reactions === Rearrangement reactions are fragmentation reactions that form new bonds producing an intermediate structure before cleavage. One of the most studied rearrangement reaction is the McLafferty rearrangement / γ-hydrogen rearrangement. This occurs in the radical cations with unsaturated functional groups, like ketones, aldehydes, carboxylic acids, esters, amides, olefins, phenylalkanes. During this reaction, γ-hydrogen will transfer to the functional group at first and then subsequent α, β-bond cleavage of the intermediate will take place. Other rearrangement reactions include heterocyclic ring fission (HRF), benzofuran forming fission (BFF), quinone methide (QM) fission or Retro Diels-Alder (RDA).

Sources: en.wikipedia.org

Reference notes

Metribolone, also known as 17α-methyltrenbolone, as well as 17α-methyl-δ9,11-19-nortestosterone or 17α-methylestra-4,9,11-trien-17β-ol-3-one, is a synthetic estrane steroid and a 17α-alkylated derivative of nandrolone (19-nortestosterone). It is the C17α methylated derivative of trenbolone (δ9,11-19-nortestosterone) and the C9- and C11-dehydrogenated (δ9,11) analogue of normethandrone (17α-methyl-19-nortestosterone). Other close relatives and derivatives of metribolone include mibolerone (7α,17α-dimethyl-19-nortestosterone) and dimethyltrienolone (RU-2420; 7α,17α-dimethyl-δ9,11-19-nortestosterone). In addition to AAS, trimethyltrienolone (R2956; 2α,2β,17α-trimethyl-δ9,11-19-nortestosterone), a highly potent antiandrogen, has been derived from metribolone.

The far-right political party Britain First received a gold checkmark, signifying that it was a business, while its leader, Paul Golding, has a blue checkmark. According to researcher Nima Owji, Twitter will allow users who have received Twitter Blue for free to cancel their subscription.

A large advertising push by Taco Bell had begun in late February 2011 in response to a consumer protection lawsuit filed against the company by an Alabama law firm. The promotion sought to counter allegations that the company falsely advertised the ratio of ingredients in its beef filling for its tacos. The spots featured employees and franchisees stating that the filling has always been a mixture of 88% beef and various spices and binders and nothing else. The ad followed several full-page print ads in the New York Times and other newspapers that featured the headline "Thank you for suing us." Additionally, the chain added a new social campaign using Twitter and Facebook. The company invested heavily in the campaign, spending more than $3 million (USD) putting out its message—about 20 percent more than the company usually spends on an advertising program. The various campaigns came shortly before the company began its official response to the suit in the United States District Court for the Central District of California and were designed to bring public opinion into their camp. Various analysts stated that the company would have been better off using a grass-root campaign that involved in store advertising and other non-broadcast media. The suit was eventually withdrawn, and the company continued its advertising response by publicly requesting an apology from the suing firm of Beasley Allen. Analyst Laura Ries, of marketing strategy firm Ries & Ries, stated she believed Taco Bell's latest response was a mistake.

Cyclic glycine-proline (cGP) is a small neuroactive peptide that belongs to a group of bioactive 2,5-diketopiperazines (2,5-DKPs) and is also known as cyclo-glycine-proline. cGP is a neutral, stable naturally occurring compound and is endogenous to the human body; found in human plasma, breast milk and cerebrospinal fluid. DKPs are bioactive compounds often found in foods. Cyclic dipeptides such as 2,5 DKPs are formed by the cyclisation of two amino acids of linear peptides produced in heated or fermented foods. The bioactivity of cGP is a property of functional foods and presents in several matrices of foods including blackcurrants. cGP is metabolite of hormone insulin-like growth factor-1 (IGF-1). It has a cyclic structure, lipophilic nature, and is enzymatically stable which makes it a more favorable candidate for manipulating the binding-release process between IGF-1 and its binding protein thereby, normalizing IGF-1 function. Under the trade name Traneurocin (developmental code name NA-831), it is being developed as a racetam-like drug for the treatment of COVID-19, Alzheimer's disease, fragile X syndrome, Rett syndrome, major depressive disorder, and other neurological disorders. In the case of COVID-19, it is specifically being developed for treatment of COVID-19-induced neuropathy.

Sources: en.wikipedia.org

Frequently asked questions

How does the reactive group attach to albumin?

A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.

Does the modification change how the peptide signals?

The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.

Are human half-life figures well established?

Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.

How is sample identity confirmed?

Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.

Network